KRAS and cancer: This was also observed in an extended panel of cancer cells lines originating from pancreatic and ovarian cancer and in primary cells derived from the transgenic PyMT (Polyoma Middle T) breast cancer mouse model and a KRAS-driven model of pancreatic cancer, as well as in primary cancer cells derived from breast cancer patients.